Tuite Paul
Department of Neurology, University of Minnesota, Minneapolis, Minnesota.
Transl Res. 2016 Sep;175:4-16. doi: 10.1016/j.trsl.2015.12.006. Epub 2015 Dec 17.
Although a magnetic resonance imaging (MRI) biomarker for Parkinson's disease (PD) remains an unfulfilled objective, there have been numerous developments in MRI methodology and some of these have shown promise for PD. With funding from the National Institutes of Health and the Michael J Fox Foundation there will be further validation of structural, diffusion-based, and iron-focused MRI methods as possible biomarkers for PD. In this review, these methods and other strategies such as neurochemical and metabolic MRI have been covered. One of the challenges in establishing a biomarker is in the selection of individuals as PD is a heterogeneous disease with varying clinical features, different etiologies, and a range of pathologic changes. Additionally, longitudinal studies are needed of individuals with clinically diagnosed PD and cohorts of individuals who are at great risk for developing PD to validate methods. Ultimately an MRI biomarker will be useful in the diagnosis of PD, predicting the course of PD, providing a means to track its course, and provide an approach to select and monitor treatments.
尽管帕金森病（PD）的磁共振成像（MRI）生物标志物仍是一个未实现的目标，但MRI方法已有诸多进展，其中一些已显示出在PD研究中的潜力。在美国国立卫生研究院和迈克尔·J·福克斯基金会的资助下，结构、基于扩散以及聚焦铁的MRI方法作为PD可能的生物标志物将得到进一步验证。在本综述中，涵盖了这些方法以及其他策略，如神经化学和代谢MRI。建立生物标志物的挑战之一在于个体的选择，因为PD是一种异质性疾病，具有不同的临床特征、病因和一系列病理变化。此外，需要对临床诊断为PD的个体以及有高风险患PD的个体队列进行纵向研究，以验证相关方法。最终，MRI生物标志物将有助于PD的诊断、预测PD的病程、提供跟踪病程的手段，并提供选择和监测治疗的方法。
